Medigene AG (FRA:MDG1)
Germany · Delayed Price · Currency is EUR 0.0172
+0.0006 (3.61%)
At close: Jun 30, 2026
Medigene AG Earnings Call Transcripts
Fiscal Year 2024
-
Capital will be refocused on off-the-shelf TCR-guided therapies, with MDG3010 as the lead program and autologous programs paused except for MDG1015, which is delayed pending financing. A 40% workforce reduction and cost measures align with the new strategy, while partnerships and financial options are actively pursued.
-
Revenue grew 45% year-over-year to EUR 4.5 million, with an improved EBITDA and extended cash runway into July 2025. Lead TCR-T program MDG1015 is on track for clinical trial initiation by year-end, supported by new partnerships and a successful capital raise.